PreMD maintains a pipeline of unique predictive medicine products and technology platforms:

All of PreMD’s products rely on sophisticated color measurement of biologic reactions. In fact, many diagnostic tests rely on interpretation of color. We believe there is a significant opportunity for PreMD to apply its proprietary color-measuring technology to other companies’ products where more precise color measurement would enhance performance.

PreMD’s cancer products are based on the same marker and use the same technology. We are exploring how this market may be applied to other sites of the body where mucus is secreted, such as the cervix.

PreMD acquired the rights to develop and commercialize Colopath™ in March 2001 from Procyon BioPharma Inc. Like ColorectAlert™, Colopath™ is a test for colorectal cancer that identifies a cancer marker in a sample of rectal mucus using a proprietary chemical process. Colopath™ is supported by multiple patents in major world markets.

PreMD previously sponsored research at McMaster University, in Hamilton, Ontario, where the company's laboratory facilities are based, aimed at using genomics to detect cancer at the earliest stages and monitor patients’ responses to gene therapy. PreMD has the first opportunity to commercialize any technologies resulting from this research.

PreMD continuously seeks out opportunities to acquire technologies that have undergone initial successful proof-of-principle tests, and that can be developed into predictive medicine products to fit a recognized medical need.